Evidence map›Paper›PMID 42305633›Full record

ArticleJournal of drug delivery science and technology2026

Protein-based nanocarrier delivering kartogenin derivative to cartilage matrix for intra-articular treatment of osteoarthritis.

Luca Morici, Sébastien Jenni, Bill Hakim, Carlos Rodríguez-Nogales, Eric Allémann, Ambika G Bajpayee, Olivier Jordan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of drug delivery science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Frontiers in pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luca MoriciSchool of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, Geneva, 1211, Switzerland.ORCID 0009-0001-7102-1285
Sébastien JenniSchool of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, Geneva, 1211, Switzerland.
Bill HakimDepartment of Bioengineering, Northeastern University, 805 Columbus Avenue, Boston, MA, 02120, USA.
Carlos Rodríguez-NogalesSchool of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, Geneva, 1211, Switzerland.ORCID 0000-0003-3280-9069
Eric AllémannSchool of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, Geneva, 1211, Switzerland.ORCID 0000-0002-6598-9521
Ambika G BajpayeeDepartment of Bioengineering, Northeastern University, 805 Columbus Avenue, Boston, MA, 02120, USA.
Olivier JordanSchool of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, Geneva, 1211, Switzerland.ORCID 0000-0003-3752-2198

Funding

Intra-cartilage depot delivery of electrically-charged IL-1RA for targeting osteoarthritis-associated inflammation and catabolism in multiple joint tissuesR01AR075121 · NIAMS · NORTHEASTERN UNIVERSITY · PI BAJPAYEE, AMBIKA GOEL · 2020 to 2025
$2.5M
NIAMS NIH HHS R01 AR075121
6 · The paper itself

Abstract

Osteoarthritis is the most common degenerative joint disease worldwide, yet no intra-articular disease-modifying osteoarthritis drugs (DMOADs) have succeeded in clinical trials due to poor therapeutic outcomes and limited cartilage targeting. Positively charged nanosized carriers have been shown to penetrate the dense, negatively charged cartilage. Here, we synthesized a cationic avidin-biotin-PEG

Indexed as

AvidinCartilageKartogeninNanocarrierOsteoarthritisProtein-based delivery system

Identifiers

PMID42305633
PMCPMC13267916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.